Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with non-myeloid malignancy~* At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless of schedule~* Hemoglobin concentration less than 11.0 g/dL within 24 hours before randomization~* Adequate serum folate and vitamin B12~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Of legal age at the time written informed consent is obtained~Exclusion Criteria:~* Known history of seizure disorder~* Known primary hematologic disorder causing anemia other than non-myeloid malignancies~* Unstable/uncontrolled cardiac condition~* Clinically significant inflammatory disease~* Other diagnoses not related to the cancer which can cause anemia~* Inadequate renal and liver function~* Iron deficiency~* Known positive test for HIV infection~* Previously suspected of or confirmed to have neutralizing antibodies to rHuEPO~* Received more than 2 red blood cell (RBC) transfusions within 4 weeks of randomization; or any RBC transfusion within 14 days before randomization; or any planned RBC transfusion between randomization and study day 1~* Received any erythropoietic therapy within 4 weeks of study day 1 or any planned erythropoietic therapy between randomization and study day 1~* Other investigational procedures~* Currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject receiving other investigational agent(s)~* Pregnant or breast feeding~* Not using adequate contraceptive precautions~* Previously randomized into this study~* Known hypersensitivity to any products to be administered~* Concerns for subject's compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darbepoetin alfa - Group A (Type: EXPERIMENTAL): None
- Placebo- Group B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).